Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PHGDH | O43175 | 12/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | PLA2G4A | P47712 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL965948 | 0.92 | LMNA (0.34) | PHGDHKMT2AUSP2PLA2G4AALDH1A1 | |
| SCHEMBL966800 | 0.92 | USP2 (0.36) | PHGDHKMT2AUSP2PLA2G4AALDH1A1 | |
| SCHEMBL963605 | 0.80 | TRPM8 (0.41) | PHGDHKMT2AALDH1A1LMNAHTT | |
| SCHEMBL963820 | 0.80 | TRPM8 (0.38) | PHGDHLMNAHTTSMN1; SMN2 | |
| SCHEMBL963628 | 0.78 | TAS2R14 (0.40) | KMT2AALDH1A1LMNASMN1; SMN2POLB | |
| SCHEMBL966630 | 0.78 | PTGDR2 (0.34) | PHGDH | |
| SCHEMBL4554170 | 0.78 | PHGDH (0.34) | PHGDHKMT2AMEN1NPY5R | |
| SCHEMBL968497 | 0.77 | MAPT (0.35) | PHGDHKMT2AUSP2PLA2G4ALMNA | |
| SCHEMBL968493 | 0.77 | MAPT (0.35) | PHGDHKMT2AUSP2PLA2G4ALMNA | |
| SCHEMBL967867 | 0.77 | PHGDH (0.35) | PHGDHKMT2APLA2G4ALMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-01-13 | — | — | US | disclosed |
| US-20080194617-A1 | Fused ring compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194617-A1 | Fused ring compound | SLC5A1, SLC5A2, GPR119 | PHGDH 1137/4885KMT2A 1809/4885USP2 4346/4885 |
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | PPARA, PPARD, PPARG | PHGDH 1142/4885KMT2A 2017/4885USP2 4289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.